These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 34077510)

  • 1. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J; Andric B; Tataradze A; Schömig M; Reusch M; Valluri U; Mariat C
    Nephrol Dial Transplant; 2021 Aug; 36(9):1616-1628. PubMed ID: 34077510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
    Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
    Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
    Provenzano R; Shutov E; Eremeeva L; Korneyeva S; Poole L; Saha G; Bradley C; Eyassu M; Besarab A; Leong R; Liu CS; Neff TB; Szczech L; Yu KP
    Nephrol Dial Transplant; 2021 Aug; 36(9):1717-1730. PubMed ID: 33629100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
    Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
    Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
    Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
    Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.